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Abstract
Impaired nerve regeneration and inadequate recovery of motor and sensory function follow-
ing peripheral nerve repair remain the most significant hurdles to optimal functional and
quality of life outcomes in vascularized tissue allotransplantation (VCA). Neurotherapeutics
such as Insulin-like Growth Factor-1 (IGF-1) and chondroitinase ABC (CH) have shown
promise in augmenting or accelerating nerve regeneration in experimental models and may
have potential in VCA. The aim of this study was to evaluate the efficacy of low dose IGF-1,
CH or their combination (IGF-1+CH) on nerve regeneration following VCA. We used an allo-
geneic rat hind limb VCA model maintained on low-dose FK506 (tacrolimus) therapy to pre-
vent rejection. Experimental animals received neurotherapeutics administered intra-
operatively as multiple intraneural injections. The IGF-1 and IGF-1+CH groups received
daily IGF-1 (intramuscular and intraneural injections). Histomorphometry and immunohis-
tochemistry were used to evaluate outcomes at five weeks. Overall, compared to controls,
all experimental groups showed improvements in nerve and muscle (gastrocnemius) histo-
morphometry. The IGF-1 group demonstrated superior distal regeneration as confirmed by
Schwann cell (SC) immunohistochemistry as well as some degree of extrafascicular regen-
eration. IGF-1 and CH effectively promote nerve regeneration after VCA as confirmed by
histomorphometric and immunohistochemical outcomes.
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Introduction
Vascularized composite allotransplantation (VCA) is the new frontier of organ transplantation
that has enabled restorative options for devastating civilian or combat craniofacial or extremity
injuries. The focus of most ongoing research in VCA is to develop novel immunomodulatory
or tolerogenic therapies to minimize or eliminate life-long immunosuppression in VCA, which
are predominantly life-enhancing procedures. Nevertheless, the life long burden of immuno-
suppression is not the only hurdle to VCA [1]. Neuroregeneration remains the other major, yet
relatively understudied barrier in VCA. Functional outcomes after clinical VCA such as upper
extremity or face transplantations have been acceptable in some patients, but in many cases,
motor and even more so sensory function, have remained unsatisfactory. Slow or sub-optimal
nerve regeneration or delayed muscle re-innervation (or denervation), could all predispose to
poor recovery. Such inadequate or ineffective nerve regeneration can result in loss of graft func-
tion, which equates to graft “failure” even in an immunologically viable graft. This is a feature
unique to VCA in contrast to solid organs. Hence, for broader feasibility of VCA, it is impera-
tive that we explore strategies that facilitate rapid and effective nerve regeneration as well as
timely distal target reinnervation. The goal of this study was to test the neurotherapeutic effi-
cacy and feasibility of Insulin-like Growth Factor-1 (IGF-1) and/or chondroitinase ABC (CH)
in VCA. These agents have been well studied in models of peripheral nerve grafts, and nerve
crush, transection and repair [2–14]. Our earlier study on the individual efficacy of CH, was
the first to demonstrate significant improvements in nerve morphometry in a stringent alloge-
neic rat limb VCA [14]. In the current study, we hypothesized that IGF-1 and CHmay have
additive, complementary or synergistic benefit in enhancing morphological and immunohisto-
logical outcomes of axonal regeneration after nerve transection and repair in VCA.
Materials and Methods
Animals and Surgical Procedures
Eight- to 12-week-old male Lewis (recipients) and Brown Norway rats (donors) [Harlan Labo-
ratories (Indianapolis, IN) (250–300g)] were used in fully mismatched limb transplantation.
Animals were anesthetized with intraperitoneal (IP) pentobarbital (40mg/kg injection) or iso-
flurane gaseous anesthesia (V-1 Lab, VetEquip Inc., CA, USA). Orthotopic hind-limb trans-
plantation was performed as described earlier [14]. Donor and recipient hind limbs were
shaved and retrieved through a circumferential skin incision, ligation of epigastric vessels,
microdissection of femoral vessels, and transection at the level of the inguinal ligament. The
donor leg was amputated at mid-femoral level with transection of the femoral vessels proxi-
mally to provide length for anastomoses. The femoral artery was flushed with 5ml of cold hepa-
rinized Ringer’s lactate solution and stored at 4°C. The recipient leg was amputated similarly
but with transection of the vessels more distally than the donor. Osteosynthesis was performed
using an 18-gauge needle for intramedullary fixation. The sciatic nerve was coaptated using
9–0 nylon sutures (Microsurgery Instruments, Inc., Bellaire, TX) and the thigh muscles were
sutured with interrupted 4–0 Vicryl sutures (Ethicon Inc., Somerville, NJ). Microsurgical anas-
tomosis of the femoral artery was performed with interrupted 11–0 nylon sutures. The femoral
vein was coapted using a cuff technique with a polyamide tube used as a microcuff (RiverTech
Medical, Chattanooga, TN).
An overdose of pentobarbital (80 mg/kg) or CO2 exposure was used for euthanasia and all
efforts were made to minimize pain and distress. This study was carried out in strict accordance
with the University of Pittsburgh Institutional Animal Care and Use Committee and American
Association for Laboratory Animal Care guidelines.
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Experimental Design
Rat recipients were allocated into five groups (n = 5). Experimental groups, dosing, route and
frequency of administration of treatments are shown in Table 1. Daily IGF-1 injections were
avoided in the CH group to eliminate any confounding effects of IGF-1. All animals received
FK506 (0.5mg/kg daily, IP) as baseline immunosuppression for five weeks (end point of experi-
ment) to prevent acute VCA rejection. We chose five weeks as our end point, as there is a
“blow-through” effect observed after nerve repair around 40 days post-surgery, whereby an
advancing nerve front overcomes an experimental nerve defect. This effect renders nerve
regeneration differences between experimental and control groups indistinguishable at late
time points (further details in Discussion).
Gastrocnemius muscles and sciatic nerves from hind limbs (operated and naïve) were har-
vested at endpoint for histomorphometric and immunohistochemical (IHC) analyses. The
total length of the rat sciatic nerve prior to branching (trifurcation) into deep muscular
branches is approximately 2 cm (20 mm). We performed coaptation of the sciatic nerve at the
middle point. To ensure that samples were collected proximal to the branching of the sciatic
nerve, we chose sites at 5 and 10 mm distal to the coaptation for histomorphometry and immu-
nostaining, respectively. We collected two samples per nerve, one fixed in glutaraldehyde (for
histomorphometry) and the other for IHC and immunofluorescent staining (S1 Fig). Quantita-
tive histomorphometry of sciatic nerves was performed on sections fixed in glutaraldehyde.
Given the limitation of available nerve tissues for sampling, some immunostaining of sciatic
nerves was done on prior resin embedded samples (after resin stripping) while other samples
were derived from cryosections after fixation in Bouin’s fixative.
Quantitative Histomorphometry
Gastrocnemius muscle. Explanted hind limbs were fixed in 2% paraformaldehyde for 24
hours. Bones were decalcified using CalRite (Thermo Scientific, MA, USA) and mid limb sec-
tions (10–20 mm thick) were embedded in paraffin. Five μmmuscle sections were cut and
stained using Mallory’s Trichrome method (Rowley Biochemical Institute, MA, USA) per
manufacturer recommendations. Cross-sectional images were evaluated blindly using bright-
field microscopy and MetaMorph Microscopy Automation and Image Analysis software
Table 1. Experimental Groups, Dosing, Administration, Frequency of Treatment.
Treatment (n = 5) Dose Site of Administration Timing
Control (PBS) 30 mL Distal nerve; sub-epineurial Prior to transection
IGF-1 200ng/30mL Distal nerve; sub-epineurial Prior to transection
200ng/30mL (IGF-1) IM After limb transplant
CH 1U/30uL Distal nerve; sub-epineurial Prior to transection
IGF-1 + CH 200ng/30mL (IGF-1) Distal nerve; sub-epineurial Prior to transection
1U/30mL (CH) Distal nerve; sub-epineurial Prior to transection
200ng/30mL (IGF-1) IM After limb transplant
PBS, phosphate buffered saline; IGF, Insulin-like growth factor-1 (Recombinant, R&D Systems, MN); CH, chondroitinase ABC (Sigma-Aldrich, MO)
The Control (PBS) and CH groups received individually administered doses as three sub epineurial injections (10μL each) along distal nerve prior to
transection.
The IGF-1 group received three sub-epineurial injections (10μL each) along distal nerve prior to transection followed by daily intramuscular injections
(200ng/30mL) into transplanted limb.
The IGF-1+CH group received three sub-epineurial injections of IGF-1 mixed with CH (30μL total volume) along distal nerve prior to transection followed
by daily intramuscular injections of IGF-1 (200ng/30mL) into transplanted limb.
doi:10.1371/journal.pone.0156149.t001
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(Version 7.7.5.0). Single line and trace region tools were used to measure perimeter of ran-
domly selected smallest and largest muscle fibers and area of muscle fascicle, respectively.
When using the line tool, we chose only well-rounded muscle fibers (S2A Fig). Measured
parameters also included number of fibers per fascicular area; mean area of a fiber calculated
from the total area of fascicle divided by the number of fibers and mean percent of connective
tissue. The images were thresholded for blue color (connective tissue) and this area was
expressed as a percent with references to total tissue.
Sciatic nerve. Sciatic nerves (2 cm long samples, including the coaptation site) were col-
lected from explanted limbs at euthanasia, and carefully mounted on wooden tongue depres-
sors. For histomorphometry, a 10 mm long nerve segment containing the coaptation site in the
middle (see S1 Fig) was cut and fixed in a cold 2.5% glutaraldehyde solution. Nerve samples
(2.5 mm long distal segment) were excised after 24 hours of fixation, post-fixed with 1%
osmium tetroxide, dehydrated in ethanol, embedded in Polybed 812 resin (Polysciences, War-
rington, PA, USA), cut into 300 nm thick nerve sections and stained with 1% toluidine blue for
light microscopy. Digital microscopy images were obtained and nerve parameters were mea-
sured with MetaMorph software. For each nerve (n = 5), a blinded observer analyzed six fields
chosen by systematic random sampling at 100x magnification [15]. Parameters included fiber
density (per 1 mm2), total number of fibers per distal area of nerve, myelin area, axon area, and
G-ratio (axon area/total fiber area). Trace region tool was used to measure nerve fiber and
axon area, from which myelin area was calculated by subtracting axon area from fiber area (see
S2B Fig). When necessary, myelin area was measured manually using the same tool. Only mye-
linated nerve fibers inside the nerve cross section were counted and analyzed. In all graphs,
naive nerve data are shown for reference only.
Immunohistochemistry and Immunofluorescence Staining
Gastrocnemius muscle. Samples were fixed in 4% paraformaldehyde and paraffin-embed-
ded and cut into 5 μm sections. After deparaffinization, rehydration, antigen retrieval with cit-
rate buffer (pH 6.0) for 30 minutes at 98°C, and blocking with normal serum, anti-pAktSer473
antibody (1:200) (Millipore, CA, USA) was applied overnight. After 24 hours, secondary bio-
tin-bound antibody (goat anti-mouse, 1:800) was applied for 30 minutes at room temperature
(RT). To amplify and then detect positive staining, we used the Vectastain ABC kit and
ImmPACT DAB Peroxidase Substrate kit, respectively (both from Vector Laboratories, CA,
USA). The sections were counterstained with hematoxylin and after dehydration, cover slipped
with Permount. A negative control (without first antibody) was included in each set of experi-
ments and negligible staining was confirmed. Staining was quantified by counting the total
number of positively labeled cells/nuclei and data presented as the percentage of positively
stained nuclei to the total number of cells per field.
Sciatic nerve. For immunohistochemistry and immunostaining, we used two different
samples of the nerve: collected 5 mm and 10 mm distal respectively, to the site of coaptation
(S1 Fig). Following nerve histomorphometry as described above, samples (5 mm segment distal
to the coaptation) were further processed for evaluation of glycosaminoglycan (GAG) content
using anti-chondroitin 4-sulphate antibody (Abcam, MA, USA), to assess the effect of CH or
IGF-1 (in the proximity of administration) on proteoglycan accumulation after nerve injury.
Prior to GAG staining, resin-embedded nerve sections were treated with saturated sodium
hydroxide for 20 min to strip off the resin from sections, washed, processed for antigen
retrieval and treated with 10% hydrogen peroxide for 20 min to remove the osmium tetroxide.
The primary antibody (1:50) was applied overnight with next day staining procedures as
described for anti-pAktSer473 antibody staining for gastrocnemius muscle.
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Nerve segments (10 mm distal to coaptation) (S1 Fig) were fixed in Bouin’s fixative for 24
hours, washed in phosphate-buffered saline (PBS) with lithium carbonate, and incubated in 5%
gelatin + 5% sucrose (PBS) overnight. Samples were cryopreserved in the gelatin+sucrose solu-
tion and 10 μm thick sections were cut on a cryotome. Before staining, sections were washed in
37°C PBS, incubated in 0.1M acetic acid solution (37°C) to eliminate gelatin residues, washed
again (every step for 10 minutes). Next, the sections were blocked with normal serum and incu-
bated with first antibody (anti-GFAP (1:100, Millipore, CA, USA), anti-S100 (1:50, Abcam,
MA, USA), anti-Krox20 (1:50, Covance, NJ, USA), anti-Oct6 (1:50, Santa Cruz Biotechnology,
CA, USA), anti-neurofilament medium chain (NF-M) (1:400) and anti-GAP43 (1:500) (both
from ThermoScientific/Pierce, IL, USA) overnight at 4°C. Sections with NF-M staining were
counterstained with FluoroMyelin according to the manufacturer’s instructions (Life Technol-
ogies, Carlsbad, CA, USA). For Oct6, antigen retrieval with pH 6.0 citrate buffer was applied
under the same conditions as mentioned for the muscle sections. Respective secondary anti-
bodies were added after washing at the dilution 1:400 or 1:800 for 30 minutes at RT. All sam-
ples were counterstained with Hoechst 33258 to visualize nuclei. A negative control was
included in every experiment. Staining was examined using NIS Elements software by measur-
ing binary area (area of positive staining) and mean intensity per field. The product of staining
was calculated by multiplying binary area by mean intensity.
All data for histomorphometry, IHC and immunostaining were collected from five-six fields
per rat (20x, n = 5 per group). Background fluorescence was subtracted as follows from all ana-
lyzed images: an image was sampled on ImageJ in a ratio and then degraded by a structuring
element; then the degraded image was subtracted from the initial image (i.e. "top hat" trans-
form). In all graphs, naive muscle data are shown for reference only.
Confocal Imaging
Samples were imaged with Olympus Fluoview 1000 confocal microscope using a 60x oil objec-
tive. Immunohistochemistry images were represented as z projections of confocal stacks
acquired from serial laser scanning. Images of overall myelin expression were acquired with a
Nikon 90i upright microscope using a 20x objective and modified using NIS-Elements software
to show only red channel (myelin expression). Muscle images were acquired with a Nikon
brightfield microscope.
Statistical Analysis
All data were imported into Prism 5.0 software (GraphPad Software Inc, CA, USA). Data
from sections containing more than one subsample were analyzed for their intra-sample het-
erogeneity. The subsamples within one section were compared and tested for normality with
Kolmogorov-Smirnov test and for heterogeneity of variance with the method of Bartlett, with a
significance level of 5%. The data showed normal distribution and heterogeneity was not signif-
icant. We used a one-way analysis of variance (ANOVA) as our study was mostly focused on
one independent variable with>2 conditions or treatments. If the ANOVA was significant (at
least one significant difference between conditions) we performed a Tukey post-hoc test to
compare two conditions at a time and determine all possible pair-wise differences (if at least
one difference was significantly different from 0). Differences were considered significant
for p< 0.05 and were marked with asterisk as follows:  p< 0.05,  p< 0.01,  p< 0.001.
Data are expressed as mean +/- standard error of the mean (mean+/-SEM., error bars) and
the reported ‘n’ values are the numbers of different individual rats from which data were
obtained.
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Results
Nerve Histomorphometry
Quantitative histomorphometric analysis of nerves is shown in Fig 1. Fiber density in the distal
part of the nerve (approximately 5 mm from coaptation) was higher in IGF-1 [mean +/- SEM:
17364+/-2831(p = 0.0243)] as compared to controls. CH (mean +/- SEM: 11649+/-2970) and
IGF-1+CH (mean +/- SEM: 10492+/-689) treatment did not result in marked improvement in
fiber density. (Fig 1A). Respectively, the total numbers of fibers per nerve area were 1.16, 1.44
and 1.28 fold higher for the IGF-1, CH, and IGF-1+CH groups as compared to controls (Fig
1B). Transplanted nerves demonstrated reduction in fiber size across groups after surgery (Fig
1D). There were also changes in the size of the nerve cross-section as demonstrated by Fig 1D,
mid panel. Nevertheless, myelin and axon area increased by 1.35 and 1.43 fold (mean +/- SEM:
8.417+/-0.1819 and 6.459+/-0.2425, p<0.001 in both) and 1.39 and 1.47 fold (mean +/- SEM:
8.658+/-0.2163 and 6.603+/-0.1979, p<0.001 in both) in the IGF-1 and CH groups versus
Fig 1. Histomorphometric characterization of nerve regeneration. (A) density of fibers in distal part of the nerve; (B) total
number of fibers per distal nerve area (manual count); (C) nerve cross-section area; (D) cross-section samples of distal nerves,
100x (upper raw, scale 10 μm) and 10x (lower raw, scale 50 μm); (E) myelin area; (F) axon area; (G) G-Ratio of nerve fibers. This
is the ratio of the axonal area to the total fiber area and is widely utilized as a functional and structural index of optimal axonal
myelination (S2B Fig).
doi:10.1371/journal.pone.0156149.g001
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controls (mean +/- SEM: 6.248+/-0.1495 and 4.506+/-0.1471), respectively. Highest increases
(mean +/- SEM: 13.81+/-0.859 and 7.939+/-0.5055) (1.76- and 2.2 fold) were seen in the IGF-1
+CH groups (Fig 1E and 1F). The G-ratio of was most improved with CH treatment (Fig 1G).
Nerve Immunohistochemistry
Multiple markers were used to establish the comprehensive temporal or dynamic aspects of
nerve regeneration within distal nerve segments. IHC with markers for progression of nerve
regeneration such as growth-associated protein (GAP43), axonal growth (Neurofilament M
(NF-M)), and characterization of SC populations (S100, GFAP, Oct6, Krox20, myelin) is
shown in Fig 2. GAP43 expression was prominent in controls, with lower intensity in IGF-1
and IGF-1+CH groups (as assessed on Tukey, p<0.5, n = 5).
When analyzing samples for SC markers, we focused our evaluation on changes in prolifera-
tion (anti-GFAP, Oct6 antibodies) and differentiation (anti-S100, Krox20). GFAP was highly
expressed in the CH group with very low expression in IGF-1 and IGF-1+CH samples (as
assessed on Tukey’s, p<0.05, n = 5). Similarly, Oct6 expression was rarely observed in the SC
nuclei in the IGF-1 and IGF-1+CH samples as compared to the CH group. Instead, its expres-
sion was found in some cells in close proximity to the nuclei that resembled its distribution in
naïve nerve (see box inserts). S100 expression was significantly decreased across groups (as
assessed on Tukey’s, p<0.05, n = 5); but SCs in the CH, IGF-1 and control samples regained on
average 26% of the expression seen in naïve nerves. Moreover, some areas of the IGF-1 treated
nerve sections had S100 expression similar to those seen in the naïve nerves (see box inserts,
“semilunar or donut” shaped areas). Staining for Krox20 was significantly higher in the IGF-1
and CH nerves versus controls (as assessed on Tukey’s, p<0.05, n = 5). In some instances, its
expression in IGF-1 samples was similar to naïve nerves (box inserts). These trends were not
observed in the remaining groups. The IGF-1+CH group had the lowest expressions of both
S100 and Krox20. Fig 3 demonstrates the levels of expression accessed by product of staining
(binary area X mean intensity) for all markers, including NFM and myelin.
We compared overall myelin expression in nerve cross-sections obtained 10 mm distal to
the coaptation site (Figs 3 and 4A–4F). We found that overall myelination increased 119, 29, and
36-fold (mean +/- SEM: 7.4+/-0.5843, 1.781+/-0.1732 and 2.249+/-0.1998, p<0.001 all) in the
IGF-1, CH, and IGF-1+CH samples versus control (mean +/- SEM: 0.0624+/-0.007), respectively.
Fig 4A–4F demonstrates examples of myelin expression in relation to axonal regrowth in groups.
Despite the substantial decrease in the expression across groups after surgery, the product of
NF-M staining was 1.8 fold higher (mean +/- SEM: 7.511+/-0.6974, p = 0.002) in the CH group
whereas in IGF-1 and IGF-1+CH nerve, the staining was 1.6- and 1.4 fold less (mean +/- SEM:
2.624+/-0.4533 and 2.925+/-0.2124) as compared to controls (mean +/- SEM: 4.165+/-0.6294),
respectively. Overall, the complex staining demonstrates advanced regeneration in the treatment
groups with superior differentiation and regeneration in the IGF-1 group.
Fig 5 shows the green channel (NF-M staining) that was intentionally switched off in Fig 4.
Here, NF-M counter-staining is shown together with myelin staining.
Anti-chondroitin-4-sulfate antibody was used to evaluate the effect of CH and IGF-1 treat-
ments on presence of growth-restricting proteoglycan at 5 weeks post-surgery (Fig 6). In naïve
nerve, the expression of chondroitin-4-sulfate was abundant in axons and SCs. Specifically,
most intense staining was observed intracellularly close to membrane area (axon and SC) in
comparison to prior studies that report transmembrane and extracellular localization of stain-
ing [16]. The expression of this proteoglycan appears to be contact-regulated [17]. Depending
on the treatment, proteoglycan was localized to axons (control, IGF-1+CH) or SC (CH group).
IGF-1 nerves had negative or only rare axonal staining.
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Fig 2. Immunohistochemical staining of the distal nerve.Regeneration marker—GAP43 (green), immature non-myelinating Schwann cells
(SCs)—GFAP (red), pre-myelinating SCs—Oct6 (red), committed non-myelinating and myelinating SCs—S100 (red), myelinating SCs—Krox20
(green) are shown. Comparison of expression to that in naïve nerves is indicated in the white boxes. The name of antigen is shown in each
column, identification for naive sample and groups is shown in rows: (A row) naive; (B) control; (C) IGF-1; (D) CH; (E) IGF-1+Ch. Magnification
60x, scale 10 μm.
doi:10.1371/journal.pone.0156149.g002
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Histomorphometry of Gastrocnemius Muscle
Muscle samples were examined with anti-pAktSer473 antibody to determine whether 200 ng
of IGF-1 was sufficient for activation of PI3K-Akt signaling in muscles. Phosphorylation of
Akt pathway at Ser473 position is known to be a marker for IGF-1 action in the tissue [18].
Fig 3. Quantitative representation of differentiation and proliferation markers. Histograms show
product of staining of differentiation markers/commited Schwann cells: (A) Krox20, (B) S100; proliferation
markers/immature Schwann cells: (C) GFAP, (D) Oct-6; nerve regeneration: (E) GAP43; axonal growth/
myelination: (F) NF-M, (G) myelin.
doi:10.1371/journal.pone.0156149.g003
Fig 4. Overall myelin expression.Magnification 20x, scale 100 μm, sections 10 mm distal to surgical coaptation site, 5 weeks post-
surgery. Images: (A) negative control (B) naive nerve; (C) control nerve; (D) CH; (E) IGF-1; (F) IGF-1+CH. Red—myelin, blue—
nucleus.
doi:10.1371/journal.pone.0156149.g004
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The number of pAkt-positive stained nuclei increased 1.9 fold in both the IGF-1 and IGF-1+
CH groups (mean +/- SEM: 58.44+/-3.996 and 58.05+/-1.826, p = 0.001 and p = 0.002, respec-
tively) compared to controls (mean +/- SEM: 31.29+/-4.827), whereas a moderate increase was
Fig 5. Neurofilament M (NF-M) (axonal marker, green) andmyelin (SCmarker, red) expression. The images were cropped from
images in Fig 4. Scale 100 μm. Images: (A) negative control; (B) naive nerve; (C) control nerve; (D) CH; (E) IGF-1; (F) IGF-1+CH.
doi:10.1371/journal.pone.0156149.g005
Fig 6. Chondroitin-4-sulphate (proteoglycan) staining in nerves at 5-week end point. Images: (A, F) naive nerve;
(B, G) control nerve; (C, H) IGF-1; (D, I) CH; (E, J) IGF-1+CH. Scale is 20μm, magnification 20x. The images F-J show
absence of staining in samples without primary antibody staining (Slight variation in background staining in these
samples may be due to persistent differences in residual resin remaining in samples).
doi:10.1371/journal.pone.0156149.g006
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seen in the CH group (Fig 7A and 7H). However, the number of positively stained nuclei in
IGF-1 treated groups was 1.5-fold less than in naïve muscles (mean +/- SEM: 89.54+/-1.225)
[Fig 7A and 7H].
Fascicular hyperplasia of gastrocnemius muscles was observed across all groups except for
IGF-1+CH treatment (Fig 7B). Although muscle cross-section area shrank by an average of
1.4-fold by the fifth week after transplantation, the mean fiber size in the CH group was bigger
(mean +/- SEM: 1355+/-83.71, p = 0.0213) than in the controls (mean +/- SEM: 1087+/-88.65)
(Fig 7C). Normal gastrocnemius muscle contains mixed fiber types: type I (slow oxidative,
small size), type IIA (fast oxidative-glycolytic, intermediate size) and type IIB fibers (fast glyco-
lytic, largest). We did not perform type-specific staining, but rather focused our analysis on
measuring perimeters of small and large fibers. The mean size of small fibers was similar across
groups except for the IGF-1+CHmuscles, which had the smallest fibers (Fig 7D). However,
Fig 7. Gastrocnemiusmuscle histomorphometry. (A) percent of pAktSer437 nuclei per muscle field (n = 3 rats); (B) number of fibers per
muscle fascicle (n = 3); (C) mean muscle fiber size calculated from the fascicular area divided by the number of fibers per fascicle (n = 3); (D)
mean perimeter of smallest muscle fiber randomly chosen in the muscle field (n = 3); (E) mean perimeter of largest muscle fiber randomly
chosen in the muscle field (n = 3); (F) mean percent of connective tissue per muscle field (n = 3); (G) example of muscles stained with
Trichrome, magnification 10x (scale 100 μm); (H) examples of pAkt-positive stained nuclei in muscles, magnification 40x.
doi:10.1371/journal.pone.0156149.g007
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large fibers in the IGF group were similar to naïve and significantly bigger than in remaining
groups (Fig 7E) (as assessed on Tukey’s, p<0.05, n = 3). Connective tissue content in both
IGF-1 and IGF-1+CH treated muscles was increased although with no statistically significant
difference (Fig 7F).
Discussion
Functional recovery after peripheral nerve injury and repair depends on multiple intrinsic and
extrinsic factors, which determine neuronal survival after axotomy. This is facilitated by myr-
iad neurotrophins and neuropoietic factors including IGF-1 and CH. IGF-1 is a not only neu-
rotrophic but also myotrophic (induces satellite cell proliferation, differentiation and muscle
hypertrophy) and angiogenic (via VEGF) [3, 10–13]. Thus it modulates multiple pathways
contributory to optimal neuroregeneration. CH on the other hand enhances nerve regeneration
and myelination, attenuates scar formation, and promotes functional nerve recovery. Primar-
ily, CH inhibits chondroitin sulfate proteoglycans (CSPGs), known negative regulators of axo-
nal regeneration after injury. CSPGs promote axonal death and prevent SC access to pro-
regenerative laminin. CH degrades the inhibitory CSPGs, thus facilitating axonal regeneration
[7–9, 14–16].
Our prior experience in rodent limb transplantation confirms that there is only a finite tem-
poral window exists for making accurate assessments of peripheral (sciatic) nerve regeneration
in this model. In prior studies (unpublished data) we found that neurotherapeutic interven-
tions (such as tacrolimus) can cause increases in fiber counts, myelin or SC parameters along
with changes in functional outcomes (as seen on Cat Walk or sciatic function index or Swim
Test) in this model. Notably, however, when compared to controls (naïve untreated animals
with neurorrhaphy) these differences in parameters were significant only up to 40 days. After
this time point, there was a “blow-through” effect observed in limb transplanted rats whereby
an advancing nerve front overcomes an experimental defect, rendering experimental groups
indistinguishable from untreated controls at late time points. In essence, there was a type II
error—in which a difference exists between groups but fails to be detected—may be more com-
mon than generally recognized. Since the rate of recovery of nerve function was the key
research question, and our goal was to preserve key differences in neurotherapeutic efficacy on
the nerves, we used a time point less than 40 days in this current study (5 weeks or 35 days).
We previously reported the effect of CH monotherapy on nerve regeneration in a similar rat
VCA model [14]. The current research differed from our prior study in multiple aspects pre-
venting a head-to-head comparison. Variables included but were not limited to differences in
dosing, route of administration, or batch (or vendor) of CH used and the software used in mea-
surements [binary image software (semi-manual) in earlier versus MetaMorph (manual) in
current study]. Nevertheless, the findings of Hattori et al. on the effects of CH [same manufac-
turer and the dose (1U/30μl) as our current study] in a nerve transection and repair model in
Sprague-Dawley rats are comparable to our current results with CH monotherapy [15]. One of
these findings included reduction in the number of extrafascicular regeneration of axons with
CH treatment. Extrafascicular and retrograde regeneration are the main cause of neuropathy,
manifesting in loss of, or abnormal nerve function over time [19]. Although, we did not study
this process in detail in our samples, some degree of extrafascicular sprouting was seen on light
microscopy examination in all groups (least marked in controls, CH and IGF-1 + CH groups
and most prominent in the IGF-1 group) (Fig 8).
IGF-1 is chemoattractive for regenerating axons and has been shown to stimulate chemo-
taxis of neuroblasts [20]. While some extrafascicular fibers resembled degenerated fibers, extra-
fascicular sprouting in IGF-1 treated nerves was associated with formation of nerve fascicles as
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shown in Fig 8. Some of the intraneurally injected IGF-1 could have extravasated into sur-
rounding tissues contributing to this phenomenon. Regardless, the effect of IGF-1 therapy on
extrafascicular or retrograde nerve regeneration merits further investigation.
Other studies report that IGF-1, unlike CH, induces dose-dependent synthesis of aggregat-
ing proteoglycans that are major growth inhibitory components of the glial scar tissue [21–25].
In our study, chondroitin-4-sulfate was present in the axons of IGF-1 and IGF-1+CH nerves
but not in CH treated nerves as demonstrated with anti-chondroitin-4-sulfate staining (Fig 6).
CH mediates clearance of proteoglycans that block intrafascicular axonal growth by suppress-
ing CSPGs [7–9].
To our knowledge, this is the first report of the use of IGF-1 (alone) or IGF-1+CH (in com-
bination) as neurotherapies in VCA. Our study confirms that IGF-1 and CHmonotherapy sig-
nificantly improves nerve and muscle regeneration. Each neurotherapeutic agent produced a
unique profile of quantitative (nerve and muscle histomorphometry) and molecular (IHC)
responses. Contrary to our a priori hypothesis, the results of combined therapy were not as
effective as IGF-1 or CH monotherapy. Interestingly, we found that the majority of nerve sam-
ples from IGF-1+CH group had high levels of hyperplasia. Fascicular area in controls, IGF-1,
and CH groups was 53.6%, 40%, and 52.3%, respectively, whereas in the IGF-1+CH group was
on average 87% more than naïve nerves (Fig 1C). Total area of myelinated fibers (MF) per
nerve cross-section was highest in IGF-1+CH (22%) and IGF-1 (17%) groups, followed by the
CH group (13%) and controls (8.5%). Fibers in the IGF-1+CH nerves were larger compared to
other groups. The total numbers of MF per nerve was similar in both IGF-1+CH and IGF-1
Fig 8. Light-microscopic overview of extrafascicular nerve zones. Toluidine blue stained sections are shown
with arrows indicating extrafascicular nerve fibers and stars indicating nerve area. (A) Control sample, (B) CH
sample, (C) IGF-1 and (D) IGF-1+CH. Magnification (20x), scale is 50μm. Insets show detail of extrafascicular
myelinated axons.
doi:10.1371/journal.pone.0156149.g008
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groups while in naive nerves, MFs occupied approximately 74% of the nerve area. The hyper-
plasia seen in IGF-1+CH nerves may be due to both increase in MF area and enlarged endo-
neurium, which includes SCs, fibroblasts, blood vessels, extracellular material, and/or a higher
number of non-myelinating axons. Indeed, the increase in cell number per nerve area in the
experimental groups was clearly evident (Figs 4 and 5). The number of cells per nerve field was
also variable; similar to variations in fascicular area. The IGF-1+CH group had a seven-fold
increase in cell number per field as compared to naïve nerves, which was the highest among all
groups. In naïve nerves, the majority of cells in the nerve cross-section are SCs, cells crucial to
overall nerve regeneration [26]. Therefore, the underlying processes of regeneration can be
revealed through characterization of their proliferation and differentiation markers such as
GFAP (immature/non-myelinating), Oct6 (pre/pro-myelinating), Krox20 and S100 (mature/
myelinating). According to IHC analysis, the majority cells in IGF-1+CH nerve were not SCs.
It is likely that they were fibroblasts representing scar tissue. The staining showed signs of poor
axonal integrity and poor expression of SC proliferation and differentiation markers. Notably,
GFAP expression was barely detectable in both IGF-1+CH and IGF-1 samples. We did not
investigate the temporal expression of GFAP in our samples, but we found a report of gradual
reduction in GFAP expression following IGF-1 treatment in a rodent model of depression [27].
Our finding may be the first report of down-regulation of GFAP after intraneural injection of
IGF-1 and merits further investigation. We used an anti-GAP43 antibody to characterize the
extent of regeneration. Similar to GFAP, GAP43 expression was slightly lower in IGF-1 and
IGF-1+CH treated groups. Earlier studies using double antibody labeling, found that both pro-
teins are co-expressed in non-myelinating SCs [26]. This may explain lower expression of both
proteins in the IGF-1+CH group. We found that the IGF-1 group demonstrated similar to
naïve nerves pattern of expression of mature (S100, Krox20) and pre-myelinating (Oct6) SC
markers (Fig 2). Moreover, gross myelin expression per cross-section in IGF-1 group was high-
est among groups, indicating normalization of SC function (Fig 4). It is known that in uncon-
trolled conditions, GAP43 expression gradually fades as neuromuscular connectivity and
innervation is established [28]. A decrease in GAP43 expression in IGF-1 nerves may also be
influenced by extrafascicular axonal regrowth into surrounding muscles. We did not evaluate
GAP43 expression outside of the nerve cross-section, but this can be addressed in future stud-
ies. Contrary to IGF-1 treated nerves, CH nerves demonstrated upregulation of most markers.
Although the intensity of Krox20 expression was similar in both groups, the stained cells did
not have the same pattern. The staining with NF-M antibody indicated the presence of many
maturing axons, but myelination was rather sparse (Figs 2 and 4), suggesting that the majority
of SCs were in the pre-myelinating stage and not in tight junctions with axons (myelination is
usually initiated by contact with axolemma) [29]. This could indicate that SCs in CH-treated
nerve were still undergoing active regeneration.
It is well documented that muscle recovery or protection from atrophy depends on timely
and adequate nerve regeneration [30]. IGF-1 or CH treatments improved nerve histomorpho-
metry, but these agents differed in their effects on nerve IHC. Similar to total nerve number,
the mean muscle area was comparable across experimental groups except for CH group. The
largest fibers were seen in the IGF-1 group while smallest fibers were found in the IGF-1+CH
group. Further investigation may be needed to evaluate whether there is positive role for the
extrafascicular effects of IGF-1 on muscle regeneration.
Taken together, our study investigated whether targeted delivery (to sites of nerve injury or
repair) of low dose IGF-1, CH, or their combination in a clinically relevant regimen (single
injection during surgery) on a background of low dose FK506 monotherapy was effective in
improving nerve regeneration after VCA. Despite improvements in some histomorphometric
and immunohistochemical parameters in neuromuscular components, our results did not fully
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support our a-priori hypothesis that combination therapy with IGF-1 and CH would boost
nerve regeneration after VCA. The finding does not completely exclude the synergistic or addi-
tive potency of these agents but rather suggests that further fine-tuning of combined neu-
rotherapies may be required. Further insights into the dosing, frequency and timing of IGF-1
and CH are needed to potentially improve and optimize their effects on neural, muscular or
vascular regeneration after VCA.
In conclusion, this study sheds preliminary insights on the promising effects of IGF-1 and
CH on histomorphometric and immunohistochemical surrogates of neuroregeneration in a
rodent VCA model. We limited our study end point to 5 weeks based on the timeline of the
“blow through” phenomenon as reported in rodent peripheral nerve regeneration [31]. How-
ever, future investigation must focus on longer-term studies in large animal pre-clinical models
that address the potential of these novel neurotherapeutic agents on improving neurofunc-
tional outcomes after VCA.
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